Samsung Biologics

Latus Launches with State-of-the-Art Gene Therapy Development Technologies, Two Lead Product Candidates, and an Initial $54 Million in Series A Financing

Retrieved on: 
목요일, 5월 2, 2024
Biotechnology, Professional Services, Health, General Health, Pharmaceutical, Other Science, Research, Genetics, Science, Clinical Trials, Finance, Doctor of Philosophy, CNS, SVP, Translational medicine, MIT, Genzyme, Cochlea, Hereditary Disease Foundation, Harvard Medical School, Toxicity, HTT, Therapy, Merck, CLN2, Hospital, Safety, Biomedical Research, Samsung Biologics, CHOP, Samsung C&T Corporation, AAV, Koch Institute, Gene expression, Central nervous system, NHP, Program management, Cell, DSM-IV codes, Patient, Gene, Society, Einstein Medical Center Philadelphia, Annual general meeting, Massachusetts General Hospital, Pharmaceutical industry

Latus Bio, Inc. (“Latus”), a biotechnology company developing novel gene therapy candidates for disorders of the central nervous system (CNS), today announced its launch and an initial close of $54 million in Series A financing.

Key Points: 
  • Latus Bio, Inc. (“Latus”), a biotechnology company developing novel gene therapy candidates for disorders of the central nervous system (CNS), today announced its launch and an initial close of $54 million in Series A financing.
  • These limitations have led to the reliance on high-dose injections that cause off-target toxicity and difficulties in scalable manufacturing.
  • The Company’s management team is composed of experienced and respected leaders in gene therapy and neuroscience.
  • Her address will showcase the Company's progress and the vast potential of its technology to solve unmet needs in CNS gene therapy.

Samsung Biologics Reports First Quarter 2024 Financial Results

Retrieved on: 
수요일, 4월 24, 2024
Consolidated, KRX, CDMO, Samsung Biologics, KRW, ADC, Growth, Samsung

INCHEON, South Korea, April 24, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced financial results for the first quarter of fiscal year 2024.

Key Points: 
  • INCHEON, South Korea, April 24, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced financial results for the first quarter of fiscal year 2024.
  • With accumulated orders exceeding USD 12.5 billion, the demand for our client-centric services remains robust," said John Rim, CEO and President of Samsung Biologics.
  • In the first quarter of 2024, Samsung Biologics reported a consolidated revenue of KRW 946.9 billion, marking a 31.3% increase from KRW 720.9 billion in the prior-year period.
  • On a standalone basis, Samsung Biologics reported KRW 669.5 billion in revenue,13.3% higher than the prior-year period, while operating profit reached KRW 232.7 billion.

Global Contract Development and Manufacturing Organization Market Analysis Report 2023-2024 and 2029: Flexible and Scalable Manufacturing Processes Shaping the CDMO Landscape - ResearchAndMarkets.com

Retrieved on: 
금요일, 3월 22, 2024
Chemicals, Plastics, Health, Manufacturing, Other Manufacturing, Pharmaceutical, Biotechnology, Catalent, CDMO, Growth, Prevalence, Cardiovascular disease, A-DNA, Application, COVID-19, Patient, Conditional sentence, Samsung Biologics, Research, Diabetes, Messenger, WuXi Biologics, Investment, Antibody, Drug development, Workforce, API, Glaucoma, Vaccine, CMOS, Fine chemical

The global contract development and manufacturing organization (CDMO) market was valued at US$124.38 billion in 2023, and is expected to be worth US$256.90 billion in 2029.

Key Points: 
  • The global contract development and manufacturing organization (CDMO) market was valued at US$124.38 billion in 2023, and is expected to be worth US$256.90 billion in 2029.
  • The "contract development manufacturing organization (CDMO)" model has emerged in response to growing demand.
  • CDMOs, third-party providers, specialize in developing and manufacturing production processes for pharmaceutical firms, offering support throughout the drug-making journey.
  • The growing importance of specialized services, spanning early-stage development to commercial manufacturing, underscores the expanding role of CDMOs in the entire drug development lifecycle.

Rapid Micro Biosystems Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Guidance

Retrieved on: 
금요일, 3월 1, 2024
Total, Investment, EST, Growth, Microbiology, Samsung Biologics, Automation, Beauty salon

LOWELL, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced its financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Strong fourth quarter 2023 revenue growth of 45% compared to the fourth quarter of 2022.
  • Total cost of revenue was $6.5 million in the fourth quarter of 2023, compared to $7.0 million in the fourth quarter of 2022.
  • Total operating expenses decreased 18% to $12.0 million in the fourth quarter of 2023, compared to $14.7 million in the fourth quarter of 2022.
  • Net loss for the fourth quarter of 2023 was $11.2 million, compared to $16.4 million in the fourth quarter of 2022.

Investor Group Submits Value-Enhancing Shareholder Proposals for Consideration at Samsung C&T Corporation’s 2024 Annual General Meeting

Retrieved on: 
금요일, 2월 2, 2024
Asset Management, Professional Services, Finance, Policy, Samsung Biologics, Growth, Samsung, CLIM, City, KRX, FY, Samsung Electronics, FCF, Electronics, Samsung C&T Corporation, KRW, KOSPI, NAV, White box, SCT, AGM, Letter, Treasury, Share repurchase, Security (finance)

Today, the Investor Group issued a letter to shareholders detailing the two value-enhancing proposals (the “Shareholder Proposals”) it has submitted for consideration at the Company’s 2024 Annual General Meeting of Shareholders (the “AGM”).

Key Points: 
  • Today, the Investor Group issued a letter to shareholders detailing the two value-enhancing proposals (the “Shareholder Proposals”) it has submitted for consideration at the Company’s 2024 Annual General Meeting of Shareholders (the “AGM”).
  • The Investor Group encourages all stakeholders to visit www.UnlockSCTValue.com to share their views, sign up for important updates and learn about the proposals to help deliver enhanced value to SCT shareholders.
  • SCT possesses an exceptionally valuable portfolio of assets that includes strategic stakes in key Samsung group affiliates (notably Samsung Electronics and Samsung Biologics) and diverse business operations spanning areas such as Engineering & Construction and Trading.
  • This is equivalent to approximately 50% of annual FCF from operations (excluding Samsung Biologics) per SCT’s own estimates for FY 2023-2025.

Samsung Biologics receives EcoVadis Platinum, the highest sustainability rating

Retrieved on: 
월요일, 1월 22, 2024
Human rights, Environment, Sustainable procurement, Samsung Biologics, Platinum, Biophysical environment, United Nations Global Compact, Accreditation, Samsung, SMI, Aviation, Labour, KRX, CDMO, Renewable energy

INCHEON, South Korea, Jan. 22, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced that the company was awarded the EcoVadis' Platinum Sustainability Rating, the highest recognition given, for the company's sustainability management.

Key Points: 
  • INCHEON, South Korea, Jan. 22, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced that the company was awarded the EcoVadis' Platinum Sustainability Rating, the highest recognition given, for the company's sustainability management.
  • Samsung Biologics received the Gold Sustainability Rating in 2022.
  • "The Platinum Rating underscores our sustainability leadership and reflects our unwavering commitment to decarbonization, ethics, and responsible business practices," said John Rim, CEO and President of Samsung Biologics.
  • Samsung Biologics has also joined global initiatives, including the Sustainable Aviation Buyers Alliance and the United Nations Global Compact.

Samsung Biologics presents 2024 business plans at J.P. Morgan Healthcare Conference

Retrieved on: 
수요일, 1월 10, 2024
Patient, ADC, Trust, Samsung Biologics, Samsung, Environment, Investment, Conference, Drug development, KRX, CDO, CDMO, Plant, Growth

INCHEON, South Korea, Jan. 9, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today presented its 2024 business plans and strategy at the J.P. Morgan Healthcare Conference held in San Francisco, California.

Key Points: 
  • INCHEON, South Korea, Jan. 9, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today presented its 2024 business plans and strategy at the J.P. Morgan Healthcare Conference held in San Francisco, California.
  • "This year, we expect to face fiercer competition and challenges as we prepare for the next decade of growth," said Rim.
  • The company is also building an antibody-drug conjugate (ADC) facility at a separate site, with the aim to commence operations by 2024.
  • "We will continue to build on our strong foundation of trust and pursue our mission to deliver high-quality biomedicines to as many patients around the world."

Samsung Biologics selects Rapid Micro Biosystems’ Growth Direct® platform to automate critical microbiology quality control testing

Retrieved on: 
목요일, 1월 4, 2024
KRX, Samsung, Microbiology, CDMO, Samsung Biologics, Automation, Growth

“Samsung Biologics is a leading global contract development and manufacturing organization (CDMO) and has demonstrated an unwavering commitment to automation and quality management in biopharmaceutical manufacturing,” said Robert Spignesi, President and CEO of Rapid Micro Biosystems.

Key Points: 
  • “Samsung Biologics is a leading global contract development and manufacturing organization (CDMO) and has demonstrated an unwavering commitment to automation and quality management in biopharmaceutical manufacturing,” said Robert Spignesi, President and CEO of Rapid Micro Biosystems.
  • “The Growth Direct® improves operational efficiency and data integrity in the quality control microbiology lab, and we are proud to partner with Samsung Biologics.”
    Global pharmaceutical manufacturers rely on the Growth Direct platform to meet both today’s microbiological quality control standards and tomorrow’s challenges.
  • It is the only fully automated, non-destructive growth-based platform for microbiology quality control testing that offers faster time to results, improved data integrity, and enhanced accuracy, with greater sample capacity.
  • To learn more about the Company and the Growth Direct® platform please visit: Rapid Micro Biosystems .

Whitebox Advisors Sends Letter to Samsung C&T Corporation’s Board of Directors Regarding Immediate Opportunities to Enhance Shareholder Value

Retrieved on: 
수요일, 12월 13, 2023
Professional Services, Asset Management, Feedback, Logic, Record, NAV, Policy, Cheil Industries, Treasury, Samsung Biologics, History, Public expenditure, Samsung Electronics, Annual general meeting, Capital, SCT, KRW, TSR, Share repurchase, White box, Return on capital employed, Growth, Samsung C&T Corporation, Letter, Samsung, Management, Financial adviser, Security (finance), Holding company, Risk management, Cryptocurrency

We are a long-term shareholder that has repeatedly sought to engage with SCT’s Board of Directors (the “Board”) and representatives of the management team in a constructive, private manner since 2017.

Key Points: 
  • We are a long-term shareholder that has repeatedly sought to engage with SCT’s Board of Directors (the “Board”) and representatives of the management team in a constructive, private manner since 2017.
  • SCT includes treasury share cancellation as part of its Shareholder Return Policy, but we would not characterise this as a shareholder return.
  • The Company has destroyed shareholder value, with a track record of decision making that appears to ignore the interests of its minority shareholders.
  • If the Board does not meaningfully engage with us on our recommendations to enhance shareholder value at SCT, we intend to share our views with our fellow shareholders in due course.

Global Healthcare Leaders Advance Sector Decarbonisation Ahead of COP28

Retrieved on: 
수요일, 11월 29, 2023
Environment, Climate Change, Infectious Diseases, Hospitals, Environmental Issues, Natural Disasters, Sustainability, General Health, Pharmaceutical, Health, Pfizer, Climate change, WHO, Patient, Climate, GSK, Novartis, BSI, Knowledge, News, NHS England, Task, Samsung Biologics, Multimedia, Air pollution, Life-cycle assessment, University of Pavia, LCA, Novo Nordisk, Johnson & Johnson, AstraZeneca, Global warming potential, Infection, University, Partnership, Water, UNICEF, Working Group, Merck Group, World Health Organization, COP26, Carbon, Reckitt, COP28, Private sector, Task force, PEG, Roche, GHG, Pharmaceutical industry, Renewable energy, Sanofi, Takeda, Lonza

This is the first time that companies from across the global healthcare sector – including AstraZeneca, GSK, Novo Nordisk, Roche – have come together to pioneer such initiatives in these countries.

Key Points: 
  • This is the first time that companies from across the global healthcare sector – including AstraZeneca, GSK, Novo Nordisk, Roche – have come together to pioneer such initiatives in these countries.
  • Today’s commitments ahead of COP28, which marks the first global climate conference to have an official focus on health, build on bold action already taken by the group to decarbonise healthcare .
  • The Working Group aims to accelerate the delivery of sustainable healthcare in China, with broader global impact.
  • Ahead of COP28, new Task Force members Bupa, Novartis and Reckitt joined the collaboration.